Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis

Daniele Santini¹, Raffaele Ratta², Francesco Pantano¹, Delia De Lisi¹, Marco Maruzzo³, Luca Galli⁴,⁶, Elisa Biasco⁴, Azzurra Farnesi⁴, Sebastiano Buti⁵, Cora Nanette Sternberg⁶, Linda Cerbone⁶, Giuseppe Di Lorenzo⁷, Silvia Spoto⁸, Michelle Sterpi¹, Ugo De Giorgi⁹, Rossana Berardi¹⁰, Mariangela Tornai¹⁰, Andrea Càmerini¹¹, Francesco Massari¹², Giuseppe Procopio² and Giuseppe Tonini¹

¹ Campus Bio-Medico University of Rome, Department of Medical Oncology, Rome, Italy
² Fondazione IRCCS, Istituto Nazionale dei Tumori, Oncology Unit 1, Milan, Italy
³ Istituto Oncologico Veneto, IOV-IRCCS, Medical Oncology 1 Unit, Padova, Italy
⁴ University Hospital of Pisa, Oncology Unit 2, Pisa, Italy
⁵ University Hospital of Parma, Medical Oncology, Parma, Italy
⁶ San Camillo and Forlanini Hospitals, Department of Medical Oncology, Rome, Italy
⁷ Department of Clinical Medicine & Surgery, Oncology Division, University Federico II, Naples, Italy
⁸ Campus Bio-Medico University of Rome, Department of Internal Medicine, Rome, Italy
⁹ IRCCS Istituto Scientifico Romagnolo per lo studio e la Cura dei Tumori, Department of Medical Oncology, Meldola, Italy
¹⁰ Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Medical Oncology Unit, Ancona, Italy
¹¹ Versilia Hospital and Istituto Toscano Tumori, Medical Oncology, Lido di Camaiore, Italy
¹² S. Orsola-Malpighi Hospital, Division of Oncology, Bologna, Italy

Correspondence to: Delia De Lisi, email: d.delisi@unicampus.it

Keywords: metastatic renal cell carcinoma (mRCC), oligoprogression, pazopanib, sunitinib, targeted therapy

Received: April 25, 2016  Accepted: June 19, 2017  Published: August 07, 2017

Copyright: Santini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Locoregional treatment with radical intent should be considered during therapy with targeted agents in patients with metastatic renal cell carcinoma (mRCC) in order to achieve a complete response, especially in the setting of an oligo-progression in one or more metastatic sites.

We retrospectively enrolled 55 patients who experienced a disease oligo-progression after at least 6 months from the beginning of first-line therapy in one or more metastatic sites radically treated with locoregional treatments. Post-first-oligo-progression overall survival (PFOPOS) and post-first-oligo-progression free survival (PFOPFS) were evaluated.

The global median PFOPOS and PFOPFS were 37 months and 14 months respectively. Patients who continued the same therapy after a locoregional treatment on a site of progression had a significantly longer mPFOPOS compared to patients who changed therapy (39 vs 11 months, p=0.014). An advantage in mPFOPOS was also observed in patients with a Memorial Sloan-Kettering Cancer Center (MSKCC) good risk score compared to patients of the intermediate risk group (39 vs 29 months, p=0.036); patients with bone metastases had a longer mPFOPOS compared to those with visceral metastases (not reached vs 31 months, p=0.045). The only independent predictor of poor prognosis, in terms of PFOPOS at multivariate analysis (p=0.007), proved out to be change of treatment after first progression.
INTRODUCTION

In the last decade, the agents targeting the vascular endothelial growth factor receptor (VEGFR) (such as sunitinib, pazopanib, axitinib, sorafenib and bevacizumab) [1-6], the mammalian target of rapamycin (mTOR) pathway (including everolimus and temsirolimus) [7, 8] and the novel immune checkpoint-inhibitor antibody nivolumab [9] have revolutionized the treatment of metastatic renal cell carcinoma (mRCC) [10].

Nevertheless the introduction of targeted agents did not completely optimize treatment of mRCC because complete response (CR) is still rarely achieved. Recent findings seem to indicate that locoregional treatment such as surgery, radiotherapy or ablative techniques may improve survival in the metastatic setting, but only few retrospective analyses about their real impact on prolonging outcomes are available to date [11, 12].

In clinical practice locoregional treatment with radical intent should be considered during targeted therapy (TT) in order to attempt a CR, particularly in the context of a slow or oligo-progression in one or more metastatic sites; however currently no evidence on the correct TT sequencing when this progression occurs is available.

The concept of oligometastatic progression was first introduced by Hellman et al. [13, 14]. It can be considered as an intermediate biological state characterized by a restricted metastatic capacity and a transitional state prior to metastatic dissemination, with a limited number of sites of metastases involved. Therefore oligoprogression may be defined as a clinical situation where a limited number of metastatic tumor sites have progressed (usually between 3 and 5), while all other metastases are controlled by systemic therapy. In general it is possible for patients with oligometastatic progression, if approached with aggressive locoregional treatments, to achieve a satisfactory long-term survival not inferior to the one of non-metastatic patients’ [14].

Clinical data indicate that the number of renal cancer patients with oligometastatic disease receiving aggressive treatment is rapidly increasing [15]. In this subset of patients it remains unclear if it is more appropriate to continue the same TT or switch to another agent when progression occurs in one or more metastatic sites radically treated with a locoregional approach. Moreover no data about outcomes and no predictive and prognostic factors are defined in this specific population. In the present retrospective multicenter study, we reviewed the medical records of patients treated with first line TT who progressed after a long disease control in one or more metastatic sites radically treated with locoregional therapy. Outcome data were compared between patients who continued the same TT and patients who switched to another TT after oligo-disease progression. We also analyzed the predictive and prognostic impact of site of progression, type of locoregional treatment and switch to another TT on post-progression OS and PFS.

PATIENTS AND METHODS

Patients

This study enrolled 55 patients with advanced and/or metastatic RCC who had progressed, after a long lasting disease control, during first-line TT in one or more metastatic sites radically treated with locoregional therapy.

We retrospectively collected data from eleven Italian centers including patients treated form May 2007 to August 2015. June 2016 was the cut-off date of the last follow-up. Additional eligibility criteria consisted of a diagnosis of clear-cell or predominantly clear-cell histology; measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) criteria; age range from 18-75 years; an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2; a good or intermediate risk group according to the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria (Motzer criteria) [16]; patients who progressed in maximum three metastatic sites radically treated with locoregional approach. Patients were excluded if they had an ECOG PS > 2, a poor MSKCC risk category and if they progressed within six months since the beginning of first-line TT. The locoregional treatments documented were surgery, radiotherapy or ablative techniques. The following data were recorded for each patient: date of nephrectomy, initial prognostic score based on Motzer criteria, date and site of oligo-progression, type of locoregional treatment, clinician’s choice of continuing or switching to another TT after progression radically treated with locoregional treatments, type of TT during the oligo progression.

End points and assessment

The primary endpoint was post-first-oligo-progression-overall survival (POPOS), defined as the time interval between the date of first-oligo-progression radically treated with locoregional therapy and the date of death or of the last follow up. The main secondary endpoint was post-first-oligo-progression-free survival (PFOPFS), defined as the time interval between first
radically treated oligo-progression in one or more metastatic sites and the second clinical or radiological progression. Type of locoregional treatment, site of progression and clinician’s choice of continuing or switching to another TT after locoregional progression were analyzed as predictive factors of PFOPFS and PFOPOS. In our analysis we prefer PFOPOS as primary endpoint since progression free survival is a surrogate of overall survival.

We also analyzed OS and PFS respectively defined as the time from the start of first line TT to death or of the last follow-up and the time from the start of first line TT to first clinical or radiological progression.

Statistical analysis

OS, PFOPOS, PFS and PFOPFS were evaluated via the Kaplan-Meier method and Mantel-Haenszel log-rank test was employed to compare survival among groups. We considered distribution of clinical variables within each of the two groups of patients (continuing the same TT vs switch). Median OS (mOS), median PFOPOS (mPFOPOS), median PFS (mPFS) and median PFOPFS (mPFOPFS) were estimated by means of KaplanMeier product-limit method, while the Mantel-Haenszel log-rank test was used for statistical inference in the formal comparison between groups. A Cox-regression model was applied to the data with multivariate approach.

Multivariable logistic regression and propensity score analysis was performed in order to evaluate variables significantly associated with the continuation of the same TT after locoregional treatment of a site of oligoprogression. All significance levels were set at a 0.05 value. SPSS software (version 19.00, SPSS, Chicago) was used for all statistical analysis. Propensity score analysis was performed in R (v3.1.1) using nearest neighbor matching with R package “MatchIt”.

RESULTS

Patient characteristics

Fifty-five patients with advanced and/or mRCC have been identified from 11 Italian centers; all patients experienced a disease oligo-progression after at least 6 months from the start of first-line therapy in one or more metastatic sites that were radically treated with a locoregional therapy.

Most patients had clear-cell histology (94.5%, N = 52); 98.2% of patients (N = 54) had undergone prior nephrectomy (Table 1). According to the MSKCC classification, 56.4% of patients (N = 31) were good risk, 41.8% of patients (N = 23) were intermediate risk and for 1 patient it was not possible to calculate the risk class; 65.5% of patients (N = 36) did not present metastases at diagnosis. The most common sites of oligo-progression were lung (N = 15) and bone (N = 10), followed by kidney (N = 8), brain and liver (N = 4 each). All patients collected presented oligo-progression in a single site. The majority of patients received sunitinib as first-line (87.3%, N = 48), followed by pazopanib (9.1%, N = 5) and sorafenib (3.6%, N = 2) (Table 2). 45.5% of patients (N = 25) received radiotherapy on the site of progression as locoregional therapy, 45.5% of patients (N = 25) underwent surgery and 9.1% (N = 5) were treated

Figure 1: Post-First-Oligo-Progression Overall Survival (PFOPOS) according to treatment change after first oligo progression.
After radical treatment on progressing sites, 83.6% of patients (N = 46) did not switch to another tyrosine kinase inhibitor (TKI) and continued the same targeted agent used before the locoregional therapy; 12.8% of patients (N = 7) switched to another therapeutic agent (3 patients received an mTOR inhibitor [mTORi] and 4 were treated with a different TKI).

Outcome analyses: post-first-oligo-progression overall survival

We evaluated mOS from disease progression in one or more sites treated with locoregional approaches, that we defined as post-first-oligo-progression overall survival (PFOPOS): mPFOPOS was 37 months (95% Confidence Interval [CI] 25.2-48.7). Patients who developed bone metastases as site of oligo-progression had a trend of longer mPFOPOS compared to those who developed visceral metastases (not reached [NR] vs 31 months, p = 0.045). Patients that received the same therapy after a locoregional treatment on progressing sites had a longer mPFOPOS compared to patients who switched to another therapy (39 vs 11 months, p = 0.014) (Figure 1). Patients with Fuhrman grade 1 and 2 presented a better mPFOPOS than patients with Fuhrman grade 3 and 4 (57 vs 37 months, p = 0.021).

None of the other variables that have been considered (such as age, gender, ECOG PS, histology and type of TKI received) were significantly associated with a prolongation in survival after the oligo-progression (Table 3). At multivariate Cox regression analysis, only change of treatment after first progression (p = 0.007, HR 6.280) was an independent predictor of poorer prognosis in terms of PFOPOS (Table 4).

Logistic regression analysis showed that brain metastases and radiotherapy at oligo-progression site were significantly associated with continuing the same TT (Supplementary Table S1 on Supplementary Materials).

Outcome analyses: post-first-oligo-progression-free survival

We also evaluated post-first-oligo-progression-free survival (PFOPFS), defined as the time interval between disease oligo-progression in one or more metastatic sites, treated with locoregional approaches, and the first subsequent clinical or radiological progression. mPFOPFS in all population was 14 months (95% CI 6.9-21). None of the variables considered (ECOG PS, age, gender, histology, Fuhrman grade, prior nephrectomy, risk group and therapy received) were significantly associated with a prolongation in PFOPFS after the locoregional treatment on oligo-progressing sites. Multivariate analysis failed to show any independent prognostic factor in terms of PFOPFS. No statistically significant difference in terms of mPFOPFS was found between patients who continued the same treatment after disease oligo-progression and those who changed therapy (15 vs 7 months, p = 0.207) with a trend in favour of patients who did not switch therapy (Figure 2).

We also compared median global PFS (defined as the sum of PFS at the primary oligo-progression plus the PFOPFS) and no statistically significant difference was found between patients who received the same treatment after oligo-progression and those who underwent a change in therapy (43 vs 34 months respectively, p = 0.339), with

### Table 1: Clinico-pathological characteristics of the overall population

| Characteristics                  | No. of patients | %   |
|----------------------------------|-----------------|-----|
| **Gender**                       |                 |     |
| Male                             | 43              | 78.2|
| Female                           | 12              | 21.8|
| **ECOG PS**                      |                 |     |
| 0-1                              | 45              | 81.8|
| >1                               | 10              | 18.2|
| **Previous nephrectomy**         |                 |     |
| Yes                              | 54              | 98.2|
| No                               | 1               | 1.8 |
| **Histology**                    |                 |     |
| Clear cell RCC                   | 52              | 94.5|
| Non-clear cell RCC               | 3               | 5.5 |
| **Sarcomatoid aspects**          |                 |     |
| No                               | 54              | 98.2|
| Yes                              | 1               | 1.8 |
| **Fuhrman grade**                |                 |     |
| NA                               | 10              | 18.2|
| G1                               | 1               | 1.8 |
| G2                               | 25              | 45.5|
| G3                               | 15              | 27.3|
| G4                               | 4               | 7.3 |
| **Metastasis at RCC diagnosis**  |                 |     |
| No                               | 36              | 65.5|
| Yes                              | 19              | 34.5|
| **MSKCC**                        |                 |     |
| Good risk                        | 31              | 56.4|
| Intermediate risk                | 23              | 41.8|
| N/A                              | 1               | 1.8 |

PS = performance status; RCC = renal cell carcinoma; MSKCC = Memorial Sloan Kettering Cancer Center with ablative techniques (cryoablation or thermoablation). After radical treatment on progressing sites, 83.6% of patients (N = 46) did not switch to another tyrosine kinase inhibitor (TKI) and continued the same targeted agent used before the locoregional therapy; 12.8% of patients (N = 7) switched to another therapeutic agent (3 patients received an mTOR inhibitor [mTORi] and 4 were treated with a different TKI).
**DISCUSSION**

In the last decade, the agents targeting the VEGFR, the mTOR pathway and the novel immune checkpointinhibitor antibody nivolumab have revolutionized the treatment of mRCC [17-20]. The majority of patients treated with targeted therapy achieve a stable disease (SD) or a partial response (PR) according to RECIST criteria as their best response, furthermore a subset of patients with favorable risk factors have a long lasting duration of response during treatment and a long survival (more than 30 months) [21, 22].

The role of locoregional treatments in mRCC has played an important role in tumor control even though only few retrospective analyses about their real impact on prolonging outcomes are available to date [11].

A matter of debate remains whether TT should be continued after CR. In 2012, Albiges and her group presented the results of a multicenter retrospective analysis including 64 patients who achieved complete response (CR) during treatment with sunitinib or sorafenib administered alone or with local approaches [23]. In this study, 53 patients (83%) stopped treatment after CR: of them, 29 patients (17 who had obtained CR with TT alone and 12 with additional local treatments) were still in CR at time of analysis, suggesting the possibility of a drug a trend in favour of the group continuing with the same agent.
holiday after achieving CR. Data about this subset of patients were also reviewed by our group in a multicenter study that retrospectively analyzed the risk of recurrence and conditional Disease-Free Survival (cDFS) in 63 patients with complete remission during treatment with TKI, alone or with local treatment in mRCC [24]. On the basis of these data we found that patients who obtained CR with the help of multimodal approaches presented lower rate of recurrence (40% vs 61%) and longer DFS compared to patients treated with TKI alone (16.5 vs 41.9 months, \( p = 0.039 \)). Moreover the rate of recurrence was higher in patients with brain (88%), pancreatic (71%) and bone metastases (50%). As far as DFS, patients who continued TKI therapy after a complete response had a longer DFS than those who stopped therapy, although the difference was not statistically significant (42.1 vs 25.1 months, \( p = 0.254 \)). Additionally two years cDFS was better in patients who were treated with multimodal treatment and continued TKIs than in the other arm of patients. In the last years, the use of locoregional therapy has increased in order to manage oligo-progressing disease and attempt a complete response. To date, no data about the correct strategy after oligo-progression are available.

In this study we retrospectively investigated the real world therapeutic strategy for patients with mRCC who experienced a disease oligo-progression after at least 6 months from the start of first-line therapy in one or more metastatic sites and were treated with a locoregional approach (surgery, radiotherapy or ablative techniques)

![Figure 2: Post-First-Oligo-Progression Free Survival (PFOPFS) according to change of treatment after first progression.](image)

| Table 4: Multivariate analyses of predictors of PFOPFS |
|--------------------------------------------------------|
| **PFOPFS** | **Multivariate Cox regression** |
|            | **HR** | **p-value** |
| MSKCC       |        |             |
| Good risk vs Intermediate risk | 1.747 | 0.337 |
| Site of first progression |        |             |
| Bone vs Visceral | 3.772 | 0.231 |
| Therapy after first progression   |        |             |
| Change vs No change | 6.280 | 0.007 |
| Fuhrman grade |        |             |
| G1+G2 vs G3+G4 | 1.156 | 0.835 |
with radical intent.

Considering the PFPOS as the primary endpoint of our analysis, we showed that continuing the same therapy after a locoregional treatment on a site of progression seems to be associated with a prolongation of median post-progression overall survival. In addition, we pointed out that patients who developed bone metastases as site of oligo-progression had a trend of longer post progression mOS compared to those who developed visceral metastases. In this regard, there are opposing literature data: some studies suggest that bone metastases have a negative impact and are associated with poor clinical outcomes in patients with mRCC [25-27]. Others show that RCC patients with less than 5 bone metastases have favorable outcomes under therapy with sunitinib [28]. This could be related to a less biological aggressiveness of progression in bone metastases compared to a progression in visceral metastases [29].

Furthermore several retrospective analyses showed that patients with single or oligo-metastatic RCC bone disease who underwent locoregional treatment presented a better overall survival and tumor control than patients with both bone and visceral metastases locally treated [11, 30, 31].

No other variables were clearly associated with a prolonged OS, except for patients with good Fuhrman grade, confirming the prognostic value of nuclear grade in RCC [32]. Thus our data seem to suggest that the continuation of the same TKI after oligo-progression represents the best clinical option.

Considering all baseline variables, we found that radiotherapy and brain metastases were significantly associated with continuing the same TT.

This may be explained by the fact that TKI and mTOR inhibitors rarely cross the blood-brain barrier, so when only brain progression occurs TT combined with radiation therapy can be safely carried out in this subset of RCC patients [33].

On the other hand, even though there was no statistically significant difference in terms of PFOPFS between patients that received the same treatment after disease oligo-progression and those that changed therapy, we observed a trend in favour of the group that continued with the same regimen. These patients recorded 15 months of additional PFS after the first oligo-progression. Furthermore, considering global PFS (defined as the sum of PFS at the primary oligo-progression plus PFOPFS), we found no statistically significant difference between patients, with a trend in favour of those who continued the same TT, suggesting that the switch to a second TT should be strongly delayed in this subset of patients.

Although the heterogeneity and the small sample size analyzed, our data suggest that continuing the same TKI after oligo-progression prolong overall survival, allowing clinicians to have further therapeutic choices in case of progression.

We could probably explain the difference between the two end-point considered, supposing that during TKI therapy resistant tumor cells are selected causing oligo-progressions, so when these sites are radically treated only tumor cells who respond to TKI remains.

Even if there are no published guidelines regarding this topic, our findings are in line with current clinical practice. Indeed, most of the patients in our records continued the same therapeutic agent after locoregional treatment on oligo-progressing sites.

The compelling finding in our study is that using the same agent, until a clear progression occurs, allows to delay the use of a different drug, therefore saving a convenient therapeutic option for later use.

However, there are several limitations to this study. First off its retrospective design increases the risk of incurring bias in data selection and analysis. Secondly, the small number of patients included might give a distorted estimate of patients’ characteristics. Thirdly, there is the discrepancy in the number of enrolled patients who continued the same therapy versus those who changed agent, seemingly a result, as mentioned before, of the current clinical practice. An interesting aspect that could be studied in a successive analysis is the evaluation of the site of progression after locoregional treatment, in order to assess if progression occurs at the same site or not. According to an exploratory analysis in a subset of patients included in the present study, it seems that the subsequent progression occurs in a different site from the first oligo-progression.

Despite these limitations, the present study is the first retrospective analysis to evaluate outcome in this specific good prognostic subset of patients, suggesting that maintaining the same drug after locoregional treatment on oligo-progressing sites should be carefully considered in RCC patients.

Considering the selective population and the differences between locoregional approaches in the institutions involved, only a retrospective analysis could be considered. Nonetheless, perspective studies are needed to identify and validate specific predictive factors associated with outcomes in this population, including standardization of the locoregional techniques for the treatment of the oligo-progression.

CONFLICTS OF INTEREST

The authors of this manuscript have no conflicts of interest to disclose.

FUNDING

This research received no specific third-party funds or grant.
REFERENCES

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczyluk C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356:115–24.

2. Sternberg CN, Davis ID, Mardiak J, Szczyluk C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28:1061–68.

3. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czyzakowski P, Dutcher J, Small EJ. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26:5422–28.

4. Escudier B, Eisen T, Stadler WM, Szczyluk C, Oudard S, Staeheur M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009; 27:3312–18.

5. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer. 2011; 104:1256–61.

6. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013; 14:552–62.

7. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A, and RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116:4256–65.

8. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Harirahan S, Motzer RJ. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014; 32:760–67.

9. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, et al, and CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373:1803–13.

10. Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017; 376:354–66.

11. Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE, Staeheur M, Powles T, Ljungberg B, Bex A. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014; 15:e549–61.

12. Firek P, Richter S, Jaelk J, Brehmer B, Heidenreich A. [Metastasectomy in renal cell cancer after neoadjuvant therapy with multi-tyrosine kinase inhibitors]. [Article in German]. Urologe A. 2012; 51:398–402.

13. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13:8–10.

14. Huang F, Wu G, Yang K. Oligometastasis and oligorecurrence: more than a mirage. Radiat Oncol. 2014; 9:230.

15. Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, Weichselbaum R. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014; 11:549–57.

16. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17:2530–40.

17. Facchini G, Perri F, Caraglia M, Pisano C, Striano S, Marra L, Fiore F, Aprea P, Pignata S, Iaffaioli RV. New treatment approaches in renal cell carcinoma. Anticancer Drugs. 2009; 20:893–900.

18. Di Lorenzo G, De Placido S, Pagliuca M, Ferro M, Lucarelli G, Rossetti S, Bossio D, Puglia L, Pigianaro P, Ascione I, De Cobelli O, Caraglia M, Aiesta M, et al. The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. Expert Opin Biol Ther. 2016; 16:1387–401.

19. Ratta R, Zappasodi R, Raggi D, Grassi P, Verzoni E, Necchi A, Di Nicola M, Salvioni R, de Baud F, Procopio G. Immunotherapy advances in uro-genital malignancies. Crit Rev Oncol Hematol. 2016; 105:52–64.

20. Grimaldi A, Santini D, Zappavigna S, Lombardi A, Misso A, Santoni M, Conti A, Porta C, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE, Staeheur M, Powles T, Ljungberg B, Bex A. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014; 15:e549–61.

21. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27:5794–99.

22. Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, et al. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. J Urol. 2015; 193:41–47.

23. Albiger L, Oudard S, Negrier S, Caty A, Gravis G, Joly
F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol. 2012; 30:482–87.

24. Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, et al. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Oncotarget. 2016; 7:33831–90. doi: 10.18632/oncotarget.8302.

25. Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schoffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Annals of oncology. 2011; 22: 794-800.

26. Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, Fontana A, Berutti A, Berardi R, Vincenzi B, Ortega C, Ottaviani D, Carteni G, et al. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. PLoS One. 2013; 8:e83026.

27. Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berutti A, Berardi R, Massari F, Vincenzi B, Ortega C, et al. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? Journal of experimental & clinical cancer research. 2015; 34:10.

28. Lu X, Gu W, Zhang H, Zhu Y, Shi G, Ye D. Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib. Oncotarget. 2016; 7:26879–87. doi: 10.18632/oncotarget.8568.

29. Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Buratti L, Tortora G, Falconi M, Montironi R, Cascinu S. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer Metastasis Rev. 2014; 33:321–31.

30. Fottner A, Szalantzy M, Wirthmann L, Stähler M, Baur-Melnyk A, Jansson V, Dürr HR. Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet Disord. 2010; 11:145.

31. Wang N, Reeves KJ, Brown HK, Fowles AC, Docherty FE, Ottewell PD, Croucher PI, Holen I, Eaton CL. The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer. Journal of experimental & clinical cancer research. 2015; 34:124.

32. Bretheau D, Lechevallier E, de Fromont M, Saulc MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer. 1995; 76:2543–49.

33. Lim ZD, Mahajan A, Weinberg J, Tannir NM. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy. Am J Clin Oncol. 2013; 36:258–60.